Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Neurologix, Inc. $35M (MarketCap) Releases Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease

|Includes:Neurologix Inc (NRGX)
Parkinson’s disease is a progressive and debilitating neurodegenerative disorder that arises from the gradual deterioration of nerve cells in the brain. It affects the control of bodily movement and is characterized by four principal symptoms: limb tremor, limb rigidity, bradykinesia (slowness of movement) and postural instability (trouble with balance). According to the National Parkinson Foundation, 1 million Americans currently have PD, and an estimated 50,000 to 60,000 new cases are diagnosed each year in the United States. Unfortunately, many patients develop complications from dopaminergic interventions, the standard therapy/ treatment used for Parkinson’s. Consequently, the need for a new type of treatment is in high demand. Today, Neurologix, Inc. (OTCBB: NRGX) announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson’s disease (PD), NLX-P101. The company is currently trading at $1.25, up $0.50 or 66.67% following this announcement.

Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of gene transfer therapies for serious disorders of the brain and CNS.  Its technology is the only gene therapy strategy currently in development which bypasses the dopamine system that patients frequently develop complications from. Neurologix's investigational AAV (adeno-associated virus) vector gene therapy, NLX-P101, is a novel, non-dopaminergic approach that uses an inhibitory gene to selectively alter the neural circuitry affected in PD and, thereby, normalize brain physiology. The Phase 2 trial results demonstrated a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported. Patients enrolled in the trial had moderate to advanced PD and were not adequately responsive to current therapies.

"Based on this data, we are confident that NLX-P101 has great potential to advance the treatment paradigm for Parkinson's patients, and to eventually offer an important, new therapy for patients with this debilitating disease.  The study investigators continue to further evaluate the detailed data and we look forward to its publication or presentation," said Clark A. Johnson, President and Chief Executive Officer of the Company. "Today's news is also important validation for our ongoing development of other technologies for neurological and psychiatric diseases, including our advanced pre-clinical program in epilepsy. Given these results, we would look to pursue a strategic transaction which will maximize value for the Company."


To view this article at World Market Media click on the link below:

Disclosure: no positions
Stocks: NRGX